SR Singh, F Ahmad, A Lal, C Yu, Z Bai, H Bennett: Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. In: |CMAJ, Band 180, Nr. 4, Februar 2009, S. 385–397, PMID 19221352, PMC 2638025 (freier Volltext), doi:10.1503/cmaj.081041
L. G. Hemkens, U. Grouven, R. Bender, C. Günster, S. Gutschmidt, G. W. Selke, P. T. Sawicki: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. In: Diabetologia. 52, 2009, S. 1732–1744, doi:10.1007/s00125-009-1418-4: One major limitation of the study is the fact that patients were not randomised to treatment groups. Although the results were adjusted for all known and available confounders, potentially relevant factors such as insulin resistance, body mass index, smoking, social status and duration of diabetes were not available and therefore could not be considered in the analyses. However, to explain the observed dose-dependent risk increase in the glargine group, these potential confounders would have to be associated with both a higher cancer risk and a higher glargine dosage. For example, we have no evidence that the glargine group included more smokers or people from a lower socioeconomic class; in fact, at baseline, the glargine group generally seemed to be healthier than the human insulin group, and these findings were consistent when comparing subgroups of patients within the same dose range (S. 1738f.)
H. M. Colhoun: Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. In: Diabetologia. 52, 2009, S. 1755–1765, doi:10.1007/s00125-009-1453-1.
N Waugh, E Cummins, P Royle, C Clar, M Marien, B Richter, S Philip: Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. In: Health technology assessment (Winchester, England), Juli 2010, Band 14, Nr. 36, S. 1–248, PMID 20646668, doi:10.3310/hta14360
SR Singh, F Ahmad, A Lal, C Yu, Z Bai, H Bennett: Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. In: CMAJ, Band 180, Nr. 4, Februar 2009, S. 385–397, PMID 19221352, PMC 2638025 (freier Volltext), doi:10.1503/cmaj.081041
W. Kaplan et al.: Effects of Mixing Glargine and Short-Acting Insulin Analogs on Glucose Control. In: Diabetes Care, 2004, Band 27, Nr. 11, S. 2739–2740, PMID 15505016, doi:10.2337/diacare.27.11.2739
SR Singh, F Ahmad, A Lal, C Yu, Z Bai, H Bennett: Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. In: |CMAJ, Band 180, Nr. 4, Februar 2009, S. 385–397, PMID 19221352, PMC 2638025 (freier Volltext), doi:10.1503/cmaj.081041
N Waugh, E Cummins, P Royle, C Clar, M Marien, B Richter, S Philip: Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. In: Health technology assessment (Winchester, England), Juli 2010, Band 14, Nr. 36, S. 1–248, PMID 20646668, doi:10.3310/hta14360
SR Singh, F Ahmad, A Lal, C Yu, Z Bai, H Bennett: Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. In: CMAJ, Band 180, Nr. 4, Februar 2009, S. 385–397, PMID 19221352, PMC 2638025 (freier Volltext), doi:10.1503/cmaj.081041
W. Kaplan et al.: Effects of Mixing Glargine and Short-Acting Insulin Analogs on Glucose Control. In: Diabetes Care, 2004, Band 27, Nr. 11, S. 2739–2740, PMID 15505016, doi:10.2337/diacare.27.11.2739
